A federal judge rejects Novo Nordisk’s request to block Eli Lilly from running advertising for its weight-loss drug(s), ruling that Novo did not show it would suffer meaningful, irreparable harm from Lilly’s campaign. The court decision comes as Novo continues its underlying legal challenge over the advertising claims.
Across outlets, the basic outcome is the same: Novo’s bid to stop the ads is denied, and the dispute over whether Lilly’s marketing is misleading or otherwise improper remains active. One recurring detail is that Novo frames parts of Lilly’s campaign as asserting superiority or being “deceptive” advertising about weight loss drugs. Coverage also emphasizes that the judge found Novo’s evidence insufficient to justify stopping the ads while the case continues.
While most reports focus on the court’s reasoning about harm and the status of Novo’s suit, they differ mainly in how they foreground related topics or the judge’s wording. Overall, the articles agree on the decision and its procedural posture, with minor variation in the specific phrasing used to describe Novo’s allegations.
